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Edited by Irmgard SinningAbstract We describe a Xenopus P2Y receptor that shares only
weak homology with members of the mammalian P2Y family,
being most similar to human P2Y11. When activated by nucleo-
tide analogs, it stimulates both calcium and cAMP mobilization
pathways, a feature unique, among mammalian P2Y receptors,
to P2Y11. Activity can be blocked by compounds known to act
as antagonists of mammalian P2Y11. Genomic synteny between
Xenopus and mammals suggests that the novel gene is a true
ortholog of P2Y11. Xenopus P2Y11 is transcribed during embry-
onic development, beginning at gastrulation, and is enriched in
the developing nervous system.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The P2Y family are G protein-coupled receptors activated
by extracellular nucleotides such as ATP, ADP and UTP [1].
In mammals, eight P2Y receptors have been cloned and proven
to be nucleotide receptors, either activating phospholipase C
(P2Y1, P2Y2, P2Y4 and P2Y6) or inhibiting adenylyl cyclase
(P2Y12, P2Y13 and P2Y14). Uniquely, P2Y11 activates both
phospholipase C and adenylyl cyclase [2,3]. In humans P2Y11
is selective for ATP [2] but in dogs it is selective for ADP [3].
Two amino acid changes in the sixth transmembrane domain
appear to be responsible for this diﬀerence [4]. To date, only
human and canine P2Y11 receptor sequences have been re-
ported. Here, we describe a Xenopus GPCR that has low se-
quence homology to previously described members of the
P2Y family yet is responsive to nucleotides, increasing both
intracellular calcium concentration and de novo production
of cAMP. Synteny between Xenopus and mammalian genomes
suggests we have identiﬁed an ortholog of P2Y11. Xenopus
P2Y11 is expressed during embryonic development and is
enriched in the nervous system.*Corresponding author. Fax: +44 020 7679 7349.
E-mail address: l.dale@ucl.ac.uk (L. Dale).
1These authors contributed equally to the work.
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2.1. Xenopus studies
Xenopus laevis IMAGE clone 3199394 (MRC Gene Service,
Cambridge, UK) was fully sequenced (Genbank accession number
AM040941). RT-PCR was performed [5] using speciﬁc primers for
p2y11 (5
0-TGCTACCAGGAGAGCCAAGATG-3 0 and 5 0-TGGGTT-
CAAGAGGATGCTTCC-3 0), ornithine decarboxylase, brachyury and
sox2 [http://www.hhmi.ucla.edu/derobertis/index.html]. Whole mount
in situ hybridization was performed as described [6]. Animal caps were
isolated from mid-blastulae (stage 8) and incubated in 50% NAM [7],
supplemented with either Xenopus eFGF (a kind gift of Dr. H. Isaacs)
or human Activin A (Sigma), until sibling control embryos had be-
come late-gastrulae (stage 13). Caps were also isolated from mid-blas-
tulae previously injected with mRNA (1 ng) for Xenopus noggin and
incubated until sibling control embryos had become mid-neurulae
(stage 17).
2.2. Activity measurements
Stably expressing pools of 13121N1-Xenopus P2Y11 cells, were se-
lected with 400 lg/ml Geneticin and propagated in phenol red-free
DMEM. cAMP production was determined using a modiﬁcation of
the method described by Salomon et al. [8]. Assays were performed
in the presence of adenosine deaminase to prevent activation of endog-
enous adenosine receptors following ATP breakdown. Cells were pre-
incubated for 30 min at 37 C in the presence of 10 lMRo 20-1724 and
2 IU/ml adenosine deaminase followed by a 10 min incubation at 37 C
in the presence of agonist. Antagonists were added during the pre-incu-
bation period. Column eﬃciency was monitored using 14C-cAMP and
the data were normalized for loading and column eﬃciencies. Intracel-
lular calcium release was measured using the Fluorometric Imaging
Plate Reader System (Molecular Devices) [9]. Cells were loaded with
dye in the presence of 2.5 mM probenecid. Antagonists were pre-incu-
bated for 30 min prior to data collection. Data were normalized for
loading eﬃciency and the peak height of the response was determined.
Nucleotide analogs were prepared as described in [13]. Where indi-
cated, 10 mM stocks of ADP and UDP were treated with hexokinase
(15 U/ml) in the presence of glucose for 90 min to remove contaminat-
ing triphosphates. Statistical analyses were performed using Student’s
t-test (unpaired, two-tailed).3. Results and discussion
3.1. Identiﬁcation of Xenopus P2Y11
A cDNA encoding a putative P2Y receptor was identiﬁed in
a search of X. laevis EST databases. The predicted 313 amino
acid protein is most closely related to its Xenopus tropicalis
ortholog, with which it shares 91% sequence identity
(Fig. 1A). Homology with mammalian P2Y receptor proteins
is very low, sharing a maximum sequence identity of only
35% with P2Y11. Analysis of the X. tropicalis genome (X. laevis
has not been sequenced) shows that the gene encoding theblished by Elsevier B.V. All rights reserved.
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Fig. 1. Comparison of Xenopus and mammalian P2Y11. (A) Alignment of X. laevis (Xl), X. tropicalis (Xt), human (Hs), and canine (Cf) P2Y11 using
ClustalW. Amino acids conserved between Xenopus and mammals are shown as white letters on a black background, and those conserved between
mammals as black letters on a gray background. Putative N-linked glycosylation sites (+), extracellular cysteines (s), and two amino acids in TM6
(ﬂ) that may determine nucleotide selectivity are all indicated. (B) Genomic location of X. tropicalis (Xt), canine (Cf) and human (Hs) P2Y11, as
determined using the Ensembl Genome Browser (http://www.ensembl.org). In all three species P2Y11 is ﬂanked by the genes for Sphingosine-1-
Phosphate Receptor 1 (Edg5), DNA Cytosine-5 Methyl Transferase 1 (DMNT1), Elongation Initiation Factor 3 Subunit 4 (EIF3S4) and Peter Pan
(PPAN). Arrows indicate orientation of transcription for each gene, which is the same in all three genomes.
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(3 0), with the former transcribed in the same orientation as
the receptor and the latter in the opposite direction
(Fig. 1B). P2Y11 is ﬂanked by PPAN (5
0) and EIF3S4 (3 0) inmost mammalian genomes for which there is available se-
quence, with P2Y11 and PPAN transcribed in the same orien-
tation and EIF3S4 transcribed in the opposite orientation
(Fig. 1B). Synteny extends 3 0 to EIF3S4, including the genes
Fig. 2. Functional responses of X. laevis P2Y11 expressed in1321N1
cells. (A) The production of cAMP and (B) the release of calcium
from intracellular stores was measured in response to 100 lM of each
of ATPcS, BzATP, 2MeSATP, 2MeSADP, ATP, ADP and UTP
The response to ATPcS in the presence of indomethacin (INDO
1 lM) reﬂects the extent of Gs-coupling of Xenopus P2Y11. Hexo
kinase (HK) has been included to dephosphorylate contaminating
ATP and UTP into the corresponding diphosphate. (C) The
inhibition of 100 lM 2MeSATP-stimulated cAMP production by
several novel and known P2 receptor antagonists, each tested a
500 lM. The data represent the mean responses ± S.E.M. of three
independent experiments, each performed in triplicate. Data are
expressed as a percentage of the response to ATPcS, the most poten
agonist at the human P2Y11 receptor. There was no response, in
either functional assay, to these nucleotides in the untransfected
1321N1 cell line.
Fig. 3. Xenopus P2Y11 is expressed during embryogenesis. (A) RT-
PCR analysis of staged Xenopus embryos using gene speciﬁc primers
for P2Y11 and ornithine decarboxylase (ODC) – (control). O = oocytes,
6 = 32 cell stage, 10 = early gastrula, 13 = early neurula, 17 = neurula,
20 = neural tube closure, 30 = early tailbud; 40 = early tadpole. – RT,
control reaction performed on stage 20 mRNA in the absence of
reverse transcriptase. (B) RT-PCR analysis showing that P2Y11 is
induced in animal caps by Activin, but not by eFGF. Caps were
isolated at stage 8 (blastulae) and incubated in either eFGF or Activin
A, which induce ventral and dorsal mesoderm, respectively, until stage
13 (late-gastrulae). Expression of brachyury (Bra), an early response
gene for both FGF and Activin, and ODC were also determined. (C)
RT-PCR analysis showing that P2Y11 expression is induced in animal
caps by Noggin, a neuralizing factor. Caps were isolated at stage 10
(gastrulae) from Noggin-injected embryos and incubated until stage 17
(neurulae). Expression of Sox2, a neural marker, and ODC were also
determined.
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tEdg5 and DMNT1. Despite the low sequence homology, syn-
teny suggests we have identiﬁed the Xenopus ortholog of mam-
malian P2Y11. To date, only human and canine P2Y11
orthologs have been described, although a P2Y11-like sequence
has been isolated from the rodent-like lagomorph species
Cavia porcellus (ATN, unpublished data), the high GC content
of which might explain why rodent P2Y11 orthologs have not
yet been reported in the literature. In humans, the ﬁrst six ami-
no acids of P2Y11 are encoded on a separate exon, permitting
intergenic splicing that creates a PPAN-P2Y11 chimeric protein
[10]. Xenopus P2Y11, however, is encoded by a single exon. The
preference of P2Y11 orthologs for ATP or ADP is inﬂuenced
by the identity of two amino acids located in TM6 [4]; these
positions are occupied by histidine (H265) and arginine (R268)
in the ATP-preferring human receptor and tyrosine (Y265)
and glutamine (Q268) in the ADP-preferring canine receptor
(Fig. 1). Xenopus P2Y11 has a histidine (H
241) and arginine
(R244) at these key positions. Seven amino acid residues in-
volved in ATP recognition by the human P2Y11 receptor have
C. Devader et al. / FEBS Letters 581 (2007) 5332–5336 5335been identiﬁed: R106, F109, S206, R268, R307, M310, within the
transmembrane domains, and E186, in the second extracellular
loop (ECL2) [11]. In Xenopus P2Y11, four of these positions
are identical (R93, F96, S182 and R244), two are conserved
(K271 and V274) and there are two candidate glutamic acid res-
idues (E160 and E165) in ECL2, which is 11 amino acids shorter
than in the human receptor.
3.2. Functional properties of the X. laevis P2Y11
A unique feature of the mammalian P2Y11 receptor, is its
ability to activate both cAMP and calcium second messenger
pathways [2,3]. To determine whether this is also true of Xeno-
pus P2Y11 this receptor was expressed in 1321N1 human astro-
cytoma cells, which do not respond to extracellular nucleotides
[12,13]. Several diﬀerent nucleotide analogs including ATPcS,
the most potent agonist at the human P2Y11 receptor [14], eli-
cit a functional response in both assays (Fig. 2A and B). There
is no statistically signiﬁcant (P = 0.61) diﬀerence in the cAMP
response to ATPcS in the presence or absence of 1 lM indo-
methacin, indicating that the observed response is due to the
activation of adenylyl cyclase and not an indirect consequence
of calcium increase. Hexokinase-treated ADP increases cAMPFig. 4. Whole mount in situ hybridization of staged Xenopus embryos. (A) V
the mesoderm of the marginal zone. Strongest expression is seen in dorsal mes
gastrula showing expression localized to the involuting dorsal mesoderm. The
marginal zone at the top. (C) Dorsal view of an early neurula showing localiz
top and posterior (post) at the bottom. (D) Dorsal view of a late neurula show
is at the bottom and posterior (post) at the top. (E) Lateral view of a stage 2
dorsal axis. The head is on the left and expression can be seen in the brain,
pronephros (pro).production above control levels (P = 0.0004), while hexoki-
nase-treated UDP does not (P = 0.43), indicating that the
diphosphate ADP has signiﬁcant activity at the Xenopus
P2Y11 receptor. We tested the ability of several novel and
known antagonists of P2Y receptors to inhibit functional re-
sponses at Xenopus P2Y11 (Fig. 2C). Reactive Blue and Reac-
tive Red are able to fully block the 2MeSATP-induced cAMP
response, Suramin and Phenol Red elicit modest blockade and
PPADS and Acid Blue are relatively ineﬀective at the highest
concentrations tested. Surprisingly, none of the antagonists
tested block the calcium responses elicited by three diﬀerent
agonists: ATPcS (100 lM), BzATP (100 lM) and 2MeSATP
(100 lM). Although we do not understand this phenomenon,
it has previously been reported that Reactive Blue was able
to inhibit ATP-induced cAMP production in HL-60 cells,
but was not able to inhibit the ATP-induced calcium response
in that cell line [15]. Our data show that the Xenopus receptor
described here exhibits functional features unique to the P2Y11
subtype of the mammalian P2Y family. When combined
with genomic synteny this data provides compelling evidence
that we have identiﬁed the Xenopus ortholog of mammalian
P2Y11.egetal view of an early gastrula showing P2Y11 transcripts localized to
oderm, above the dorsal blastopore lip (dlp). (B) Section through early
animal pole (ap) is to the right, vegetal pole (vp) to the left, and dorsal
ed expression of P2Y11 in the neural plate (np). Anterior (ant) is at the
ing localized expression of P2Y11 in the neural tube (nt). Anterior (ant)
8 embryo showing that P2Y11 transcripts are enriched in the head and
eye, otic vesicle (ov), branchial arches (ba), neural tube, somites and
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Xenopus embryos were collected at diﬀerent stages of devel-
opment and poly A+ mRNA puriﬁed and reverse-transcribed
for RT-PCR. Transcripts for P2Y11 were ﬁrst detected, at
low levels, in early gastrulae (stage 10), with higher levels of
expression detected from early neurulae (stage 13) onwards
(Fig. 3A). Whole mount in situ hybridization showed that
P2Y11 transcripts were localized to the involuting dorsal meso-
derm of early gastrulae (Fig. 4A and B), a region of the em-
bryo that is both an important signaling center and an area
of extensive cell and tissue movements. Using an animal cap
assay we showed that P2Y11 expression is induced by Activin,
a dorsal mesoderm inducing factor, but not by eFGF, a ventral
mesoderm inducing factor (Fig. 3B), consistent with expression
of P2Y11 in the dorsal mesoderm of early gastrulae. At neural
plate stages P2Y11 transcripts, like those of P2Y8 [16], are
localized to the developing nervous system (Fig. 4C and D)
and expression is induced in animal caps by Noggin, a neural-
izing factor (Fig. 3C). P2Y11 is expressed throughout the dor-
sal axis at tailbud stages, with staining in the brain, eye, lens,
otic vesicle, brachial arches, spinal cord, notochord, somites,
and pronephric kidney (Fig. 2).
Our results are the ﬁrst to demonstrate a cAMP-coupled
nucleotide receptor in Xenopus. Nucleotide signaling via the
P2Y11 receptor may take place through both the calcium and
cAMP pathways during Xenopus development. The develop-
mental consequences of this dual signaling capability remain
to be elucidated.
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